Ligand Pharmaceuticals.
biopharmaceutical company based out of La Jolla, California
- Reports this week
- 0
- Active events
- 0
- Connections
- 53
What's happening
Earlier this month
One to three months ago
-
Ligand Pharmaceuticals appointed Todd Davis as CEO, acquired a 56% stake in Pelthos Therapeutics Inc., and secured royalty rights on ZELSUVMI sales.Some support4 reports2 developments inside
-
Ligand Pharmaceuticals committed funding and royalty rights to AvenCell Therapeutics, Inc.Some support1 report
-
Director Jason Haas sold shares of Ligand Pharmaceuticals on September 13, 2026, which traded on the Nasdaq.Some support1 report
-
Ligand Pharmaceuticals received FDA approval for its drug Filspari and was listed on the Nasdaq stock exchange.Some support2 reports
Gone quiet
No new reports in 90+ days-
Ligand Pharmaceuticals formed drug development partnerships with Amgen, Merck KGaA, and Pfizer.Some support2 reports2 developments inside
-
Ligand Pharmaceuticals funds drug development in partnership with Merck.Some support1 report
-
Ligand Pharmaceuticals received a rating increase and price target raise from Bank of America on August 5, while the company also listed its stock on Nasdaq.Some support1 report
-
Analyst increased price target and rating for Ligand Pharmaceuticals.Some support1 report
-
Gibbs Wealth Management increased its holdings in Ligand Pharmaceuticals in Q1 and sold shares in July 2026.Some support1 report
-
Geode Capital Management increased its stake in Ligand Pharmaceuticals and filed required reports with the SEC.Some support1 report
-
Ligand Pharmaceuticals stock trades on Nasdaq, with Citigroup issuing buy ratings and a director selling shares.Some support2 reports
-
Ligand Pharmaceuticals trades on Nasdaq, receiving analyst upgrades from Citigroup and Bank of America.Some support1 report
-
Ligand Pharmaceuticals stock trades on Nasdaq; Bank of America provides coverage and rating reports; required 13F reports are filed with the SEC.Some support1 report
-
Ligand Pharmaceuticals' subsidiary LNHC and Pelthos Therapeutics formed a merger.Speculative2 reports
-
Ligand Pharmaceuticals, based in La Jolla, CA, benefits from the current investment environment in the US market.Some support1 report
-
BofA Securities and Citigroup served as co-lead underwriters for an offering involving Ligand Pharmaceuticals on August 22, 2025.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Ligand Pharmaceuticals this week
News at the entities that move Ligand Pharmaceuticals most-
FDA StructuralFDA issued a warning letter to NeoGen regarding a product quality defect on October 7, 2026.Moves Ligand Pharmaceuticals
-
SEC StructuralMSCI index rules may affect Bitcoin companies, while warnings caused stock market crashes in Turkey and Indonesia.Moves Ligand Pharmaceuticals
-
Citigroup TransactionalMorgan Stanley and Citigroup cut AutoNation's rating and price objective on November 6, 2026.Moves Ligand Pharmaceuticals
-
representative TransactionalLocal activists are pressuring an elected representative to abolish ICE following the proposal of a detention center in Tri-Valley.Moves Ligand Pharmaceuticals
-
Pfizer OperationalA building collapse occurred in Brooklyn, following prior structural issues in a Manhattan skyscraper that was formerly Pfizer's headquarters.Moves Ligand Pharmaceuticals
-
Nasdaq StructuralWindward Bio successfully listed on the Nasdaq exchange and is a portfolio company of Qiming Venture Partners.Moves Ligand Pharmaceuticals
Connections
The 21 strongest of 53, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
representative Transactional
Representative purchased shares of Ligand Pharmaceuticals.
-
Merck Structural
The companies are in a partnership where Merck funds Ligand's drug development and provides royalty revenue from its portfolio.
-
Todd Davis Structural
Todd Davis holds the role of CEO for Ligand Pharmaceuticals.
-
Pfizer Operational
Ligand Pharmaceuticals and Pfizer maintain ongoing partnerships for drug development and supply.
-
SEC Structural
Ligand Pharmaceuticals is subject to formal disclosure and oversight requirements mandated by the SEC.
-
Nasdaq Structural
Ligand Pharmaceuticals is a company that lists and trades its stock on the Nasdaq exchange.
-
Citigroup Transactional
Citigroup has acted as a co-lead underwriter and provided investment ratings for Ligand Pharmaceuticals.
-
FDA Structural
The FDA provides formal regulatory approval necessary for Ligand Pharmaceuticals' drug products to enter the market.
Show all 21 connections
-
Merck KGaA Operational
Ligand Pharmaceuticals and Merck KGaA maintain ongoing partnerships and alliances for drug development.
-
Jason Haas Structural
Jason Haas holds a formal director role in Ligand Pharmaceuticals.
-
Amgen Operational
Ligand Pharmaceuticals and Amgen maintain an ongoing partnership for drug development.
-
Securities and Exchange Commission Structural
Ligand Pharmaceuticals must file required 13F reports with the Securities and Exchange Commission.
-
Royal Bank of Canada Mentioned together
Royal Bank of Canada provides financial analysis, including target price and rating reports, for Ligand Pharmaceuticals.
-
LinkedIn Structural
Ligand Pharmaceuticals utilizes LinkedIn as a platform for investor relations and corporate disclosure.
-
Geode Capital Management Transactional
Geode Capital Management increased its equity stake in Ligand Pharmaceuticals during the quarter.
-
Servier Structural
The relationship is functional, based on assets acquired via a specific XOMA Royalty deal.
-
Gil Cisneros Transactional
Gil Cisneros purchased shares of Ligand Pharmaceuticals.
-
Gildan Activewear Mentioned together
Both Gildan Activewear and Ligand Pharmaceuticals are noted as publicly traded companies.
-
Bank of America Mentioned together
Bank of America provides market coverage and rating reports for Ligand Pharmaceuticals.
-
Constellation Brands Mentioned together
Based on the evidence, no direct competitive link is mentioned between Constellation Brands and Ligand Pharmaceuticals.
-
Booking Holdings Mentioned together
No direct relationship or coupling between Booking Holdings and Ligand Pharmaceuticals was observed in the provided evidence.
History
Events by the month they beganNovember 2026
1 eventSeptember 2026
3 events- Ligand Pharmaceuticals committed funding and royalty rights to AvenCell Therapeutics, Inc.
- Director Jason Haas sold shares of Ligand Pharmaceuticals on September 13, 2026, which traded on the Nasdaq.
- Ligand Pharmaceuticals received FDA approval for its drug Filspari and was listed on the Nasdaq stock exchange.
August 2026
3 eventsShow 2 earlier months
July 2026
2 eventsJune 2026
8 events- Ligand Pharmaceuticals appointed Todd Davis as CEO, acquired a 56% stake in Pelthos Therapeutics Inc., and secured royalty rights on ZELSUVMI sales.
- Ligand Pharmaceuticals formed drug development partnerships with Amgen, Merck KGaA, and Pfizer.
- Ligand Pharmaceuticals stock trades on Nasdaq, with Citigroup issuing buy ratings and a director selling shares.
- Ligand Pharmaceuticals trades on Nasdaq, receiving analyst upgrades from Citigroup and Bank of America.
- Ligand Pharmaceuticals stock trades on Nasdaq; Bank of America provides coverage and rating reports; required 13F reports are filed with the SEC.
- Ligand Pharmaceuticals' subsidiary LNHC and Pelthos Therapeutics formed a merger.
- Ligand Pharmaceuticals, based in La Jolla, CA, benefits from the current investment environment in the US market.
- BofA Securities and Citigroup served as co-lead underwriters for an offering involving Ligand Pharmaceuticals on August 22, 2025.